These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 35357885)

  • 21. Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features.
    Cazaubiel T; Leleu X; Perrot A; Manier S; Buisson L; Maheo S; Do Souto Ferreira L; Lannes R; Pavageau L; Hulin C; Marolleau JP; Voillat L; Belhadj K; Divoux M; Slama B; Brechignac S; Macro M; Stoppa AM; Sanhes L; Orsini-Piocelle F; Fontan J; Chretien ML; Demarquette H; Mohty M; Schavgoulidze A; Avet-Loiseau H; Corre J
    Blood; 2022 Apr; 139(17):2666-2672. PubMed ID: 35171994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents.
    Muccio VE; Saraci E; Gilestro M; Gattei V; Zucchetto A; Astolfi M; Ruggeri M; Marzanati E; Passera R; Palumbo A; Boccadoro M; Omedè P
    Cytometry B Clin Cytom; 2016 Jan; 90(1):81-90. PubMed ID: 26287276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vitamin D deficiency linked to abnormal bone and lipid metabolism predicts high-risk multiple myeloma with poorer prognosis.
    Bao L; Wang YT; Lu MQ; Chu B; Shi L; Gao S; Fang LJ; Xiang QQ; Ding YH; Liu X; Zhao X; Wang MZ; Chen Y; Hu WK
    Front Endocrinol (Lausanne); 2023; 14():1157969. PubMed ID: 37181039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic aberrations and survival in plasma cell leukemia.
    Tiedemann RE; Gonzalez-Paz N; Kyle RA; Santana-Davila R; Price-Troska T; Van Wier SA; Chng WJ; Ketterling RP; Gertz MA; Henderson K; Greipp PR; Dispenzieri A; Lacy MQ; Rajkumar SV; Bergsagel PL; Stewart AK; Fonseca R
    Leukemia; 2008 May; 22(5):1044-52. PubMed ID: 18216867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Causes of death in primary plasma cell leukemia differ from multiple myeloma: A STROBE-compliant descriptive study based on SEER database.
    Ge X; Meng W; Wang W; Ma H; Zhao S; Cui K
    Medicine (Baltimore); 2022 Jul; 101(29):e29578. PubMed ID: 35866755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis.
    Jimenez-Zepeda VH; Dominguez-Martinez VJ
    Int J Hematol; 2009 Apr; 89(3):259-268. PubMed ID: 19326058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.
    Katodritou E; Terpos E; Kelaidi C; Kotsopoulou M; Delimpasi S; Kyrtsonis MC; Symeonidis A; Giannakoulas N; Stefanoudaki A; Christoulas D; Chatziaggelidou C; Gastari V; Spyridis N; Verrou E; Konstantinidou P; Zervas K; Dimopoulos MA
    Am J Hematol; 2014 Feb; 89(2):145-50. PubMed ID: 24123068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Global methylation patterns in primary plasma cell leukemia.
    Todoerti K; Calice G; Trino S; Simeon V; Lionetti M; Manzoni M; Fabris S; Barbieri M; Pompa A; Baldini L; Bollati V; Zoppoli P; Neri A; Musto P
    Leuk Res; 2018 Oct; 73():95-102. PubMed ID: 30257227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma cell leukemia: a rare condition.
    Jiménez-Zepeda VH; Domínguez VJ
    Ann Hematol; 2006 Apr; 85(4):263-7. PubMed ID: 16416115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of esterase gene expression in multiple myeloma.
    Kumari R; Majumder MM; Lievonen J; Silvennoinen R; Anttila P; Nupponen NN; Lehmann F; Heckman CA
    Br J Cancer; 2021 Apr; 124(8):1428-1436. PubMed ID: 33531688
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
    Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
    JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma.
    Kaiser MF; Hall A; Walker K; Sherborne A; De Tute RM; Newnham N; Roberts S; Ingleson E; Bowles K; Garg M; Lokare A; Messiou C; Houlston RS; Jackson G; Cook G; Pratt G; Owen RG; Drayson MT; Brown SR; Jenner MW
    J Clin Oncol; 2023 Aug; 41(23):3945-3955. PubMed ID: 37315268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomics of Plasma Cell Leukemia.
    Rojas EA; Gutiérrez NC
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma.
    Bertamini L; Oliva S; Rota-Scalabrini D; Paris L; Morè S; Corradini P; Ledda A; Gentile M; De Sabbata G; Pietrantuono G; Pascarella A; Tosi P; Curci P; Gilestro M; Capra A; Galieni P; Pisani F; Annibali O; Monaco F; Liberati AM; Palmieri S; Luppi M; Zambello R; Fazio F; Belotti A; Tacchetti P; Musto P; Boccadoro M; Gay F
    J Clin Oncol; 2022 Sep; 40(27):3120-3131. PubMed ID: 35666982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary Plasma Cell Leukemia: Identity Card 2016.
    Musto P; Simeon V; Todoerti K; Neri A
    Curr Treat Options Oncol; 2016 Apr; 17(4):19. PubMed ID: 26995215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of circulating plasma cells detected by flow cytometry in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis.
    Liu X; Wu F; Ye W; Deng J; Zhang M; Zhang C; Yu Q; Cao L; Gan S; Ma J
    BMJ Open; 2024 Jan; 14(1):e071548. PubMed ID: 38216195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A clinical perspective on plasma cell leukemia; current status and future directions.
    Tuazon SA; Holmberg LA; Nadeem O; Richardson PG
    Blood Cancer J; 2021 Feb; 11(2):23. PubMed ID: 33563906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The clinical characteristics of patients with primary plasma cell leukemia and the efficacy of novel agents and hematopoietic stem cell transplantation].
    Li WJ; Wang FR; Wen L; Chen Y; Chen H; Huang XJ; Lu J
    Zhonghua Nei Ke Za Zhi; 2020 Oct; 59(10):801-806. PubMed ID: 32987483
    [No Abstract]   [Full Text] [Related]  

  • 39. Primary plasma cell leukemia: A report of two cases of a rare and aggressive variant of plasma cell myeloma with the review of literature.
    Gangadhar P; Ahmed Z; Pai MR; Sandhya I
    Indian J Pathol Microbiol; 2016; 59(4):541-544. PubMed ID: 27721294
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia.
    Chang H; Qi X; Yeung J; Reece D; Xu W; Patterson B
    Leuk Res; 2009 Feb; 33(2):259-62. PubMed ID: 18676019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.